IPOS's copy

9709980-9

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40, 9/16, 9/20, 47/48 — A1

(11) International Publication Number: WO 97/09980

(43) International Publication Date: 20 March 1997 (20.03.97)

(21) International Application Number: PCT/EP96/03719

(22) International Filing Date: 21 August 1996 (21.08.96)

(30) Priority Data:
1) 9518953.6 15 September 1995 (15.09.95) GB

(71) Applicant *(for all designated States except GB JP US)*: 1) PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; La Touche House, International Financial Services Centre, Dublin 1 (IE).

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for JP only)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: 1) DOLAN, Thomas, Francis [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB); 2) HUMPHREY, Michael, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB); 3) NICHOLS, Donald, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States: AU, BR, CA, CN, CU, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR, US, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

1 PD
1 Appln.
3 Invs.



(54) Title: PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN

(57) Abstract

There is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the dosage form is adapted to deliver at least 10 % by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of the patient. The formulation minimizes unwanted side-effects and increases the bioavailability of darifenacin.